ABSTRACT
Background Lassa fever (LF) is a viral disease transmitted between animals and humans, commonly found in West Africa, including Nigeria. The region experiences an estimated annual total of about 2 million LF cases in humans, leading to 5,000 to 10,000 deaths. Strikingly, up to 80% of LF-infected individuals show no symptoms, making its true incidence hard to determine in endemic populations. We investigated LF distribution, mortality, survival patterns, and contributing factors during a local outbreak in Nigeria, from 2017 to 2021.
Method Data from the Integrated Disease Surveillance and Response weekly line list for 2017 to 2021 were extracted. The survival pattern of LF patients was visualized with the Kaplan-Meier curve, binary logistic regression model was employed to explore LF-associated factors and level of statistical significance (α) was set at 5%.
Result Overall, 4,554 participants were recruited between 2017 and 2021. Their average age varied from 31.82 ± 20.0 to 37.85 ± 17.89. LF-positive patients decreased from 26.9% in 2017 to 17.7% in 2021, paralleling the mortality trend. In 2021, patient survival ranged from 5 to 30 days. Male patients had lower survival odds in the initial 10 days of hospitalization, improved chances from days 10 to 20, and reduced probabilities beyond day 20. Residence location and age were significant factors (p<0.05) associated with LF in Ondo State.
Conclusion The decline in LF cases in 2021 could be attributed to the ongoing intervention by Nigerian Centre for Disease Control or the disruption caused by the COVID-19 pandemic in 2020. To address LF challenges in hotspot areas, we propose Community Action Networks that would operate using the One Health approach involving local stakeholders sustainably to promote Early Warning/Early Response system in high-risk settings and mitigate LF-related issues.
SUMMARY Lassa fever (LF) is an important disease of global public health concern that is endemic in West Africa. In Nigeria, the disease constitutes a major health challenge with outbreaks being recorded on an annual basis despite efforts channeled towards combating it by the government at various levels. This study analysed a five years data of LF in Ondo State southwestern Nigeria. The results identified age and location were identified as important factors associated with infection and mortality among LF patients as the incidence and case fatality rates were highest among adults (≥ 45 years), while the highest number of suspected, confirmed and dead cases was recorded in Owo Local Government Area. Furthermore, we identified drying of food items by the roadside where rodent vectors can access them, presence of a local market, poor and unsafe sewage disposal, and proximity of refuse dumps to residential areas as possible socio-ecological factors/practices fueling the endemicity and seasonal outbreak of LF. These findings emphasize the need for active involvement of community members in the already established national LF surveillance network to facilitate prompt case identification, and early reporting and response in the LF-endemic areas of the country.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was received from the Surveillance and Epidemiology Unit of Ondo State Ministry of Health and University of Ibadan/University College Hospital Institutional Review Board (UI/UCH/22/0305).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors hereby declare the all the data sets used in writing this manuscript will be made available on request at any stage of the manuscript review.
